Literature DB >> 18519881

Psychopharmacology in HIV-infected patients.

Martin J Repetto1, John M Petitto.   

Abstract

Neuropsychiatric disorders and syndromes may be underdiagnosed and inadequately treated in individuals infected with HIV. Depression in particular is among the most prevalent diagnoses, and data from controlled clinical studies have shown that antidepressant medications are efficacious and safe for treating depression in HIV-infected persons. A significant shortcoming of this literature is that most of the available data are from studies conducted before the advent of highly active antiretroviral therapy. In addition, apart from antidepressant medications, controlled studies systematically assessing efficacy and safety issues for other classes of psychotropic drugs (e.g., antipsychotic and anxiolytic medications) in HIV-infected persons are lacking. This review summarizes essential findings pertaining to the use of psychotropic medications to treat depression and other neuropsychiatric disorders in the context of HIV. It includes a discussion of clinically relevant treatment considerations (e.g., side effects, drug-drug interactions) derived from the existing literature as well as judgments that clinicians face in the absence of research data. Despite some shortcomings of the existing literature, overall there is compelling evidence that the appropriate use of psychotropic medications (coupled with behavioral therapy) can improve the quality of life of mentally ill HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519881     DOI: 10.1097/PSY.0b013e3181777190

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  10 in total

1.  NeuroAIDS: a watershed for mental health and nervous system disorders.

Authors:  Jennifer A McCombe; Farshid Noorbakhsh; Craig Buchholz; Michael Trew; Christopher Power
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

2.  A randomized controlled trial of mindfulness-based stress reduction to manage affective symptoms and improve quality of life in gay men living with HIV.

Authors:  Bill Gayner; Mary Jane Esplen; Peter DeRoche; Jiahui Wong; Scott Bishop; Lynn Kavanagh; Kate Butler
Journal:  J Behav Med       Date:  2011-05-20

Review 3.  Depression in HIV infected patients: a review.

Authors:  Maria Giulia Nanni; Rosangela Caruso; Alex J Mitchell; Elena Meggiolaro; Luigi Grassi
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

4.  Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction.

Authors:  Matthew J Geraci; Stacey L McCoy; Paul M Crum; Rajnikant A Patel
Journal:  Int J Emerg Med       Date:  2010-05-26

Review 5.  HIV and depression: 2008 review and update.

Authors:  Judith G Rabkin
Journal:  Curr HIV/AIDS Rep       Date:  2008-11       Impact factor: 5.071

6.  Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD).

Authors:  Jon Salemi; Demian F Obregon; Anthony Cobb; Spenser Reed; Edin Sadic; Jingji Jin; Francisco Fernandez; Jun Tan; Brian Giunta
Journal:  Mol Neurodegener       Date:  2011-01-11       Impact factor: 14.195

7.  Levels of self-reported depression and anxiety among HIV-positive patients in Albania: a cross-sectional study.

Authors:  Shane D Morrison; Vilson H Banushi; Clea Sarnquist; Valbona H Gashi; Lars Osterberg; Yvonne Maldonado; Arjan Harxhi
Journal:  Croat Med J       Date:  2011-10-15       Impact factor: 1.351

8.  Effect of HIV infection on time to recovery from an acute manic episode.

Authors:  E Nakimuli-Mpungu; B Mutamba; S Nshemerirwe; Ms Kiwuwa; S Musisi
Journal:  HIV AIDS (Auckl)       Date:  2010-09-29

9.  Potential drug interactions in patients given antiretroviral therapy.

Authors:  Wendel Mombaque Dos Santos; Silvia Regina Secoli; Stela Maris de Mello Padoin
Journal:  Rev Lat Am Enfermagem       Date:  2016-11-21

Review 10.  Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.

Authors:  Milo Gatti; Fabrizio De Ponti; Federico Pea
Journal:  CNS Drugs       Date:  2021-04-18       Impact factor: 5.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.